Kura Oncology (NASDAQ:KURA) COO Kathleen Ford Sells 6,902 Shares of Stock

Kura Oncology, Inc. (NASDAQ:KURA) COO Kathleen Ford sold 6,902 shares of the business’s stock in a transaction dated Friday, November 14th. The stock was sold at an average price of $11.18, for a total value of $77,164.36. Following the sale, the chief operating officer directly owned 105,373 shares of the company’s stock, valued at $1,178,070.14. This represents a 6.15% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Kathleen Ford also recently made the following trade(s):

• On Monday, September 29th, Kathleen Ford sold 6,892 shares of Kura Oncology stock. The shares were sold at an average price of $8.94, for a total transaction of $61,614.48.

Kura Oncology Trading Up 4.9%

Shares of NASDAQ:KURA traded up $0.52 during trading on Friday, hitting $11.20. 4,478,689 shares of the company’s stock were exchanged, compared to its average volume of 2,241,571. The company has a current ratio of 5.12, a quick ratio of 5.12 and a debt-to-equity ratio of 0.02. The firm has a market cap of $974.60 million, a P/E ratio of -4.52 and a beta of 0.35. The firm has a 50-day moving average price of $9.46 and a two-hundred day moving average price of $7.48. Kura Oncology, Inc. has a 1-year low of $5.41 and a 1-year high of $16.68.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.85) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.28). Kura Oncology had a negative net margin of 208.48% and a negative return on equity of 65.42%. The business had revenue of $20.75 million during the quarter, compared to analyst estimates of $17.48 million. Equities analysts predict that Kura Oncology, Inc. will post -2.44 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on KURA. UBS Group lifted their price objective on Kura Oncology from $14.00 to $16.00 and gave the stock a “buy” rating in a research note on Friday. Wedbush restated an “outperform” rating and set a $38.00 target price (up previously from $36.00) on shares of Kura Oncology in a report on Friday. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price target on shares of Kura Oncology in a research note on Friday. Wall Street Zen upgraded shares of Kura Oncology from a “sell” rating to a “hold” rating in a research report on Sunday, August 17th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kura Oncology in a research note on Wednesday, October 8th. Ten research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $25.11.

Institutional Trading of Kura Oncology

A number of large investors have recently bought and sold shares of KURA. EverSource Wealth Advisors LLC lifted its stake in Kura Oncology by 392.8% in the third quarter. EverSource Wealth Advisors LLC now owns 3,854 shares of the company’s stock valued at $34,000 after buying an additional 3,072 shares in the last quarter. PNC Financial Services Group Inc. raised its holdings in shares of Kura Oncology by 127.2% during the third quarter. PNC Financial Services Group Inc. now owns 6,732 shares of the company’s stock worth $60,000 after acquiring an additional 3,769 shares during the period. State of Wyoming bought a new stake in Kura Oncology in the 1st quarter valued at $48,000. Merit Financial Group LLC bought a new stake in Kura Oncology in the 3rd quarter valued at $89,000. Finally, Lazard Asset Management LLC boosted its stake in Kura Oncology by 222.3% in the 3rd quarter. Lazard Asset Management LLC now owns 10,423 shares of the company’s stock worth $92,000 after purchasing an additional 7,189 shares during the period.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.